vs
Side-by-side financial comparison of BELDEN INC. (BDC) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $696.4M, roughly 1.0× BELDEN INC.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 7.3%, a 11.7% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 11.4%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $-63.1M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 7.3%).
Belden Inc. is an American, multinational, publicly traded company specializing in the design, manufacture, and distribution of end-to-end networking, security and connectivity products. The company serves the Industrial Automation Solutions, Smart Buildings and Broadband & 5G markets.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
BDC vs MEDP — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $696.4M | $708.5M |
| Net Profit | $51.0M | $135.1M |
| Gross Margin | 37.1% | — |
| Operating Margin | 11.2% | 21.6% |
| Net Margin | 7.3% | 19.1% |
| Revenue YoY | 11.4% | 32.0% |
| Net Profit YoY | -1.8% | 15.5% |
| EPS (diluted) | $1.30 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $696.4M | — | ||
| Q4 25 | $720.1M | $708.5M | ||
| Q3 25 | $698.2M | $659.9M | ||
| Q2 25 | $672.0M | $603.3M | ||
| Q1 25 | $624.9M | $558.6M | ||
| Q4 24 | $666.0M | $536.6M | ||
| Q3 24 | $654.9M | $533.3M | ||
| Q2 24 | $604.3M | $528.1M |
| Q1 26 | $51.0M | — | ||
| Q4 25 | $67.9M | $135.1M | ||
| Q3 25 | $56.7M | $111.1M | ||
| Q2 25 | $61.0M | $90.3M | ||
| Q1 25 | $51.9M | $114.6M | ||
| Q4 24 | $58.4M | $117.0M | ||
| Q3 24 | $53.7M | $96.4M | ||
| Q2 24 | $49.0M | $88.4M |
| Q1 26 | 37.1% | — | ||
| Q4 25 | 36.6% | — | ||
| Q3 25 | 37.7% | — | ||
| Q2 25 | 38.5% | — | ||
| Q1 25 | 39.3% | — | ||
| Q4 24 | 37.5% | — | ||
| Q3 24 | 37.3% | — | ||
| Q2 24 | 37.5% | — |
| Q1 26 | 11.2% | — | ||
| Q4 25 | 12.2% | 21.6% | ||
| Q3 25 | 10.9% | 21.5% | ||
| Q2 25 | 11.8% | 20.9% | ||
| Q1 25 | 11.6% | 20.3% | ||
| Q4 24 | 10.4% | 23.4% | ||
| Q3 24 | 11.5% | 21.1% | ||
| Q2 24 | 11.4% | 19.9% |
| Q1 26 | 7.3% | — | ||
| Q4 25 | 9.4% | 19.1% | ||
| Q3 25 | 8.1% | 16.8% | ||
| Q2 25 | 9.1% | 15.0% | ||
| Q1 25 | 8.3% | 20.5% | ||
| Q4 24 | 8.8% | 21.8% | ||
| Q3 24 | 8.2% | 18.1% | ||
| Q2 24 | 8.1% | 16.7% |
| Q1 26 | $1.30 | — | ||
| Q4 25 | $1.70 | $4.65 | ||
| Q3 25 | $1.41 | $3.86 | ||
| Q2 25 | $1.53 | $3.10 | ||
| Q1 25 | $1.27 | $3.67 | ||
| Q4 24 | $1.41 | $3.67 | ||
| Q3 24 | $1.30 | $3.01 | ||
| Q2 24 | $1.19 | $2.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $272.2M | $497.0M |
| Total DebtLower is stronger | $1.3B | — |
| Stockholders' EquityBook value | $1.3B | $459.1M |
| Total Assets | — | $2.0B |
| Debt / EquityLower = less leverage | 0.98× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $272.2M | — | ||
| Q4 25 | $389.9M | $497.0M | ||
| Q3 25 | $314.3M | $285.4M | ||
| Q2 25 | $301.5M | $46.3M | ||
| Q1 25 | $259.0M | $441.4M | ||
| Q4 24 | $370.3M | $669.4M | ||
| Q3 24 | $323.0M | $656.9M | ||
| Q2 24 | $564.8M | $510.9M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $459.1M | ||
| Q3 25 | $1.2B | $293.6M | ||
| Q2 25 | $1.2B | $172.4M | ||
| Q1 25 | $1.2B | $593.6M | ||
| Q4 24 | $1.3B | $825.5M | ||
| Q3 24 | $1.2B | $881.4M | ||
| Q2 24 | $1.2B | $763.6M |
| Q1 26 | — | — | ||
| Q4 25 | $3.5B | $2.0B | ||
| Q3 25 | $3.4B | $1.8B | ||
| Q2 25 | $3.4B | $1.6B | ||
| Q1 25 | $3.3B | $1.9B | ||
| Q4 24 | $3.3B | $2.1B | ||
| Q3 24 | $3.3B | $2.1B | ||
| Q2 24 | $3.5B | $1.9B |
| Q1 26 | 0.98× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $192.7M |
| Free Cash FlowOCF − Capex | $-63.1M | $188.1M |
| FCF MarginFCF / Revenue | -9.1% | 26.6% |
| Capex IntensityCapex / Revenue | 6.4% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $180.4M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $160.4M | $192.7M | ||
| Q3 25 | $105.0M | $246.2M | ||
| Q2 25 | $82.0M | $148.5M | ||
| Q1 25 | $7.4M | $125.8M | ||
| Q4 24 | $174.7M | $190.7M | ||
| Q3 24 | $91.7M | $149.1M | ||
| Q2 24 | $83.0M | $116.4M |
| Q1 26 | $-63.1M | — | ||
| Q4 25 | $121.3M | $188.1M | ||
| Q3 25 | $65.3M | $235.5M | ||
| Q2 25 | $56.9M | $142.4M | ||
| Q1 25 | $-24.8M | $115.8M | ||
| Q4 24 | $116.4M | $183.0M | ||
| Q3 24 | $67.2M | $138.5M | ||
| Q2 24 | $61.0M | $103.5M |
| Q1 26 | -9.1% | — | ||
| Q4 25 | 16.8% | 26.6% | ||
| Q3 25 | 9.4% | 35.7% | ||
| Q2 25 | 8.5% | 23.6% | ||
| Q1 25 | -4.0% | 20.7% | ||
| Q4 24 | 17.5% | 34.1% | ||
| Q3 24 | 10.3% | 26.0% | ||
| Q2 24 | 10.1% | 19.6% |
| Q1 26 | 6.4% | — | ||
| Q4 25 | 5.4% | 0.6% | ||
| Q3 25 | 5.7% | 1.6% | ||
| Q2 25 | 3.7% | 1.0% | ||
| Q1 25 | 5.2% | 1.8% | ||
| Q4 24 | 8.8% | 1.4% | ||
| Q3 24 | 3.7% | 2.0% | ||
| Q2 24 | 3.6% | 2.4% |
| Q1 26 | — | — | ||
| Q4 25 | 2.36× | 1.43× | ||
| Q3 25 | 1.85× | 2.22× | ||
| Q2 25 | 1.34× | 1.65× | ||
| Q1 25 | 0.14× | 1.10× | ||
| Q4 24 | 2.99× | 1.63× | ||
| Q3 24 | 1.71× | 1.55× | ||
| Q2 24 | 1.69× | 1.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BDC
Segment breakdown not available.
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
